Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion type Assertion NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_head.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion description "[SEMG-1 is expressed in nearly half of patients with early CLL and may be a target for further investigations into its use for immunotherapy of early CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_provenance.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion evidence source_evidence_literature NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_provenance.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion SIO_000772 19241194 NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_provenance.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion wasDerivedFrom befree-20140225 NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_provenance.
- NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_assertion wasGeneratedBy ECO_0000203 NP348001.RAKKeLGBkqczLavHfpUwo9uNLltIp2OfyNhyJIEdeuU3Q130_provenance.